ATAI Life Sciences NV ATAI

Healthcare

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

NDAQ:ATAI - Post by User

ATAI Life Sciences NV

Bullboard Posts

Next >>

Post by AwareInvestoron Jun 18, 2021 7:54am

166 Views

Post# 33410019

Atai Life Sciences Increases IPO To $225 Million

Atai Life Sciences late last night announced the pricing of its upsized initial public offering. The clinical-stage biotech firm now expects its IPO to raise gross proceeds of roughly $225.0 million for the company.

https://thedeepdive.ca/atai-life-sciences-increases-ipo-to-225-million/

Bullboard Posts

Next >>

Regulatory clarity for market evolution: Canada’s position in global crypto industry